Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,656 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Schizophrenia and Disorders With Psychotic Features Clear all

Conditions: Schizophrenia, Autism Spectrum Disorder
Interventions: Oxytocin, Placebo Comparator; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease, fMRI
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 2,802 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
Interventions: mobile application; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 61 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Bipolar I Disorder, Schizophrenia
Interventions: Iloperidone; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Schizophrenia
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psychosis, Suicide, Health Care Utilization, Family Members
Interventions: Youth-Nominated Support Teams for CHR; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Irvine, California

Conditions: Schizophrenia
Interventions: PERSERIS, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 16 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: Risperidone, divalproex; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Audio Visual Hallucinations, Neurofeedback, Schizophrenia, Superior Temporal Gyrus
Interventions: rt-fMRI neurofeedback; Other
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Brockton, Massachusetts

Conditions: Bipolar Disorder, Schizophrenia
Interventions: Not listed
Lead sponsor: Jess G. Fiedorowicz; Other
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 26
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more

Conditions: Schizophrenia
Interventions: Targeted cognitive training (TCT), Computer games; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia
Interventions: L-tetrahydropalmatine (30mg), Sugar pill; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Diabetes, Obesity, Weight Gain
Interventions: Lifestyle Balance; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Long Beach, California • Sepulveda, California • West Los Angeles, California

Conditions: Schizophrenia
Interventions: ABT-126; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 20 Years to 66 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Chino, California • Costa Mesa, California • Escondido, California + 23 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more

Conditions: Schizophrenia
Interventions: RBP-7000; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 42 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Willingboro, New Jersey

Conditions: Schizophrenia
Interventions: Cognitive Adaptation Therapy (CAT), Minimal Environmental Supports (MES); Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hallucinations, Auditory, Psychosis
Interventions: Rivastigmine Transdermal System, Scopolamine, Placebo Patch; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Dyad Oxytocin Study (DOS)

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Mobile Self-Tracking of Mental Health

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

The Partners Genetics Collaborative Study of Schizophrenia

Youth Nominated Support Team

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

Rt-fMRI Neurofeedback and AH in Schizophrenia

Antipsychotics and Blood Vessel Function

Safety and Tolerability Study of Drug to Treat Schizophrenia

Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000

Treating Thought Problems in Patients With Schizophrenia

Toward a Computationally-Informed, Personalized Treatment for Hallucinations